BACKGROUND: The guaiac faecal occult blood test (G-FOBT) is recommended as a screening test for colorectal cancer but its low sensitivity has prevented its use throughout the world. METHODS: We compared the performances of the reference G-FOBT (non-rehydrated Hemoccult II test) and the immunochemical faecal occult blood test (I-FOBT) using different positivity cut-off values in an average risk population sample of 10,673 patients who completed the two tests. Patients with at least one test positive were asked to undergo colonoscopy. RESULTS: Using the usual cut-off point of 20 ng/ml haemoglobin, the gain in sensitivity associated with the use of I-FOBT (50% increase for cancer and 256% increase for high risk adenoma) was balanced by a decrease in specificity. The number of extra false positive results associated with the detection of one extra advanced neoplasia (cancer or high risk adenoma) was 2.17 (95% confidence interval 1.65-2.85). With a threshold of 50 ng/ml, I-FOBT detected more than twice as many advanced neoplasias as the G-FOBT (ratio of sensitivity = 2.33) without any loss in specificity (ratio of false positive rate = 0.99). With a threshold of 75 ng/ml, associated with a similar positivity rate to G-FOBT (2.4%), the use of I-FOBT allowed a gain in sensitivity of 90% and a decrease in the false positive rate of 33% for advanced neoplasia. CONCLUSIONS: Evidence in favour of the substitution of G-FOBT by I-FOBT is increasing, the gain being more important for high risk adenomas than for cancers. The automated reading technology allows choice of the positivity rate associated with an ideal balance between sensitivity and specificity.
BACKGROUND: The guaiac faecal occult blood test (G-FOBT) is recommended as a screening test for colorectal cancer but its low sensitivity has prevented its use throughout the world. METHODS: We compared the performances of the reference G-FOBT (non-rehydrated Hemoccult II test) and the immunochemical faecal occult blood test (I-FOBT) using different positivity cut-off values in an average risk population sample of 10,673 patients who completed the two tests. Patients with at least one test positive were asked to undergo colonoscopy. RESULTS: Using the usual cut-off point of 20 ng/ml haemoglobin, the gain in sensitivity associated with the use of I-FOBT (50% increase for cancer and 256% increase for high risk adenoma) was balanced by a decrease in specificity. The number of extra false positive results associated with the detection of one extra advanced neoplasia (cancer or high risk adenoma) was 2.17 (95% confidence interval 1.65-2.85). With a threshold of 50 ng/ml, I-FOBT detected more than twice as many advanced neoplasias as the G-FOBT (ratio of sensitivity = 2.33) without any loss in specificity (ratio of false positive rate = 0.99). With a threshold of 75 ng/ml, associated with a similar positivity rate to G-FOBT (2.4%), the use of I-FOBT allowed a gain in sensitivity of 90% and a decrease in the false positive rate of 33% for advanced neoplasia. CONCLUSIONS: Evidence in favour of the substitution of G-FOBT by I-FOBT is increasing, the gain being more important for high risk adenomas than for cancers. The automated reading technology allows choice of the positivity rate associated with an ideal balance between sensitivity and specificity.
Authors: M Zappa; G Castiglione; E Paci; G Grazzini; T Rubeca; P Turco; E Crocetti; S Ciatto Journal: Int J Cancer Date: 2001-04-01 Impact factor: 7.396
Authors: Wai Man Wong; Shiu Kum Lam; Kwan Lok Cheung; Teresa Sze Man Tong; Paul Rozen; Graeme P Young; Kin Wah Chu; Judy Ho; Wai Lun Law; Hiu Ming Tung; Hok Kwok Choi; Yee Man Lee; Kam Chuen Lai; Wayne H C Hu; Chi Kuen Chan; Man Fung Yuen; Benjamin Chun-Yu Wong Journal: Cancer Date: 2003-05-15 Impact factor: 6.860
Authors: Sidney Winawer; Robert Fletcher; Douglas Rex; John Bond; Randall Burt; Joseph Ferrucci; Theodore Ganiats; Theodore Levin; Steven Woolf; David Johnson; Lynne Kirk; Scott Litin; Clifford Simmang Journal: Gastroenterology Date: 2003-02 Impact factor: 22.682
Authors: M F Kaminski; M Bretthauer; A G Zauber; E J Kuipers; H-O Adami; M van Ballegooijen; J Regula; M van Leerdam; T Stefansson; L Påhlman; E Dekker; M A Hernán; K Garborg; G Hoff Journal: Endoscopy Date: 2012-06-21 Impact factor: 10.093
Authors: L Hol; J A Wilschut; M van Ballegooijen; A J van Vuuren; H van der Valk; J C I Y Reijerink; A C M van der Togt; E J Kuipers; J D F Habbema; M E van Leerdam Journal: Br J Cancer Date: 2009-04-07 Impact factor: 7.640